Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review
BackgroundPatients with refractory membranous nephropathy (MN) face risks of progressive renal decline and end-stage renal disease (ESRD), with limited treatment efficacy. Telitacicept, a novel humanized recombinant fusion protein effective in lupus nephritis and immunoglobulin A nephropathy (IgAN),...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1571616/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850151202015150080 |
|---|---|
| author | Shucheng Chen Yiqi Huang Zhongjie Qu |
| author_facet | Shucheng Chen Yiqi Huang Zhongjie Qu |
| author_sort | Shucheng Chen |
| collection | DOAJ |
| description | BackgroundPatients with refractory membranous nephropathy (MN) face risks of progressive renal decline and end-stage renal disease (ESRD), with limited treatment efficacy. Telitacicept, a novel humanized recombinant fusion protein effective in lupus nephritis and immunoglobulin A nephropathy (IgAN), has few reports on its use in refractory MN.Case presentationIn May 2023, an 82-year-old man was admitted to Shaoxing Second Hospital with bilateral lower extremity edema. A renal biopsy confirmed idiopathic membranous nephropathy (IMN). Standard therapies, including glucocorticoids (GC), cyclophosphamide (CYC), tacrolimus (TAC), and rituximab (RTX), were ineffective. He developed steroid-induced diabetes and acute renal failure during treatment. Complete proteinuria remission was achieved with telitacicept monotherapy. The patient is under ongoing clinical follow-up.ConclusionTelitacicept holds promise as a potential second-line therapy for refractory MN when conventional treatments prove ineffective. However, due to the current lack of robust evidence supporting its use in IMN, further research is warranted to establish its clinical efficacy and safety. |
| format | Article |
| id | doaj-art-ff715d0c524c471e8ee2fa1fce5b87d4 |
| institution | OA Journals |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-ff715d0c524c471e8ee2fa1fce5b87d42025-08-20T02:26:20ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-04-011210.3389/fmed.2025.15716161571616Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature reviewShucheng Chen0Yiqi Huang1Zhongjie Qu2Department of Endocrinology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaDepartment of Nephrology, Shaoxing Second Hospital, Shaoxing, Zhejiang, ChinaDepartment of Nephrology, The Third Affiliated Hospital of Zhejiang Chinese Medical University (Zhongshan Hospital of Zhejiang Province), Hangzhou, Zhejiang, ChinaBackgroundPatients with refractory membranous nephropathy (MN) face risks of progressive renal decline and end-stage renal disease (ESRD), with limited treatment efficacy. Telitacicept, a novel humanized recombinant fusion protein effective in lupus nephritis and immunoglobulin A nephropathy (IgAN), has few reports on its use in refractory MN.Case presentationIn May 2023, an 82-year-old man was admitted to Shaoxing Second Hospital with bilateral lower extremity edema. A renal biopsy confirmed idiopathic membranous nephropathy (IMN). Standard therapies, including glucocorticoids (GC), cyclophosphamide (CYC), tacrolimus (TAC), and rituximab (RTX), were ineffective. He developed steroid-induced diabetes and acute renal failure during treatment. Complete proteinuria remission was achieved with telitacicept monotherapy. The patient is under ongoing clinical follow-up.ConclusionTelitacicept holds promise as a potential second-line therapy for refractory MN when conventional treatments prove ineffective. However, due to the current lack of robust evidence supporting its use in IMN, further research is warranted to establish its clinical efficacy and safety.https://www.frontiersin.org/articles/10.3389/fmed.2025.1571616/fulltelitaciceptrefractory idiopathic membranous nephropathyPLA2Rcase reportliterature review |
| spellingShingle | Shucheng Chen Yiqi Huang Zhongjie Qu Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review Frontiers in Medicine telitacicept refractory idiopathic membranous nephropathy PLA2R case report literature review |
| title | Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review |
| title_full | Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review |
| title_fullStr | Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review |
| title_full_unstemmed | Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review |
| title_short | Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review |
| title_sort | telitacicept monotherapy for refractory idiopathic membranous nephropathy a case report and literature review |
| topic | telitacicept refractory idiopathic membranous nephropathy PLA2R case report literature review |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1571616/full |
| work_keys_str_mv | AT shuchengchen telitaciceptmonotherapyforrefractoryidiopathicmembranousnephropathyacasereportandliteraturereview AT yiqihuang telitaciceptmonotherapyforrefractoryidiopathicmembranousnephropathyacasereportandliteraturereview AT zhongjiequ telitaciceptmonotherapyforrefractoryidiopathicmembranousnephropathyacasereportandliteraturereview |